Company news
Rapport Therapeutics, Inc. (NASDAQ:RAPP) news
Rapport Therapeutics, Inc. news releases on 6ix. Latest, Aug 24, 2026: Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania…
Press releases & updates
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
August 24, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 7, 2026
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
April 21, 2026
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
March 31, 2026
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 9, 2026
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
March 8, 2026
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 6, 2026
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 4, 2025
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
November 24, 2025
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
November 5, 2025
Rapport Therapeutics to Participate in Upcoming Investor Conferences
November 4, 2025
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 10, 2025
Rapport Announces Pricing of Public Offering of Common Stock
September 8, 2025
Rapport Announces Proposed Public Offering of Common Stock
September 7, 2025
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
September 7, 2025
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
September 4, 2025
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
August 6, 2025
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
June 1, 2025
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
May 26, 2025
Rapport Therapeutics to Host 2025 Investor and Analyst Day
May 20, 2025
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
May 7, 2025
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
March 20, 2025
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
March 2, 2025
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 8, 2025
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
December 5, 2024
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
November 13, 2024
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
November 6, 2024
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
November 3, 2024
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
September 4, 2024
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
August 28, 2024
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 7, 2024
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
July 28, 2024
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 11, 2024